Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Arix Bioscience

DB:3HY
Snowflake Description

Reasonable growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
3HY
DB
£76M
Market Cap
  1. Home
  2. DE
  3. Diversified Financials
Company description

Arix Bioscience plc, formerly known as Perceptive Bioscience Investments Limited, is a venture capital firm specializing in seed, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The last earnings update was 23 days ago. More info.


Add to Portfolio Compare Print
  • Arix Bioscience is a fund or ETF! Currently our data availability for these is poor, we only recommend using them as part of a portfolio.
  • Arix Bioscience has significant price volatility in the past 3 months.
3HY Share Price and Events
7 Day Returns
-5.1%
DB:3HY
-6.8%
DE Capital Markets
-2.7%
DE Market
1 Year Returns
-59.9%
DB:3HY
-11.8%
DE Capital Markets
-20.4%
DE Market
3HY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Arix Bioscience (3HY) -5.1% -28.3% -45.2% -59.9% -69.4% -
DE Capital Markets -6.8% -21.9% -18% -11.8% -29% -57.8%
DE Market -2.7% -18.4% -26.7% -20.4% -25.9% -30.4%
1 Year Return vs Industry and Market
  • 3HY underperformed the Capital Markets industry which returned -11.8% over the past year.
  • 3HY underperformed the Market in Germany which returned -20.4% over the past year.
Price Volatility
3HY
Industry
5yr Volatility vs Market

Value

 Is Arix Bioscience undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Arix Bioscience. This is due to cash flow or dividend data being unavailable. The share price is €0.655.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Arix Bioscience's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Arix Bioscience's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:3HY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in GBP £-0.54
LSE:ARIX Share Price ** LSE (2020-04-01) in GBP £0.59
Germany Capital Markets Industry PE Ratio Median Figure of 17 Publicly-Listed Capital Markets Companies 22.18x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.15x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Arix Bioscience.

DB:3HY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= LSE:ARIX Share Price ÷ EPS (both in GBP)

= 0.59 ÷ -0.54

-1.09x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arix Bioscience is loss making, we can't compare its value to the DE Capital Markets industry average.
  • Arix Bioscience is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Arix Bioscience's expected growth come at a high price?
Raw Data
DB:3HY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.09x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Germany Capital Markets Industry PEG Ratio Median Figure of 7 Publicly-Listed Capital Markets Companies 1.55x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Arix Bioscience, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Arix Bioscience's assets?
Raw Data
DB:3HY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in GBP £1.55
LSE:ARIX Share Price * LSE (2020-04-01) in GBP £0.59
Germany Capital Markets Industry PB Ratio Median Figure of 32 Publicly-Listed Capital Markets Companies 1.55x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:3HY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= LSE:ARIX Share Price ÷ Book Value per Share (both in GBP)

= 0.59 ÷ 1.55

0.38x

* Primary Listing of Arix Bioscience.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arix Bioscience is good value based on assets compared to the DE Capital Markets industry average.
X
Value checks
We assess Arix Bioscience's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Capital Markets industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Capital Markets industry average (and greater than 0)? (1 check)
  5. Arix Bioscience has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Arix Bioscience expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
140.2%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Arix Bioscience expected to grow at an attractive rate?
  • Arix Bioscience is expected to become profitable in the next 1-3 years, this is considered above the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Unable to compare Arix Bioscience's earnings growth to the Germany market average as no estimate data is available.
  • Arix Bioscience's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:3HY Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:3HY Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 140.2%
Germany Capital Markets Industry Earnings Growth Rate Market Cap Weighted Average 40%
Germany Capital Markets Industry Revenue Growth Rate Market Cap Weighted Average 0.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.3%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:3HY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:3HY Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 0 -8 1
2021-12-31 0 -8 1
2020-12-31 0 -9 11 1
2020-04-02
DB:3HY Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-12-31 -58 -8 -70
2019-09-30 -40 -9 -49
2019-06-30 -22 -9 -28
2019-03-31 15 -10 5
2018-12-31 53 -11 37
2018-09-30 47 -10 31
2018-06-30 42 -9 25
2018-03-31 25 -9 9
2017-12-31 7 -9 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Arix Bioscience is expected to become profitable in the next 1-3 years, this is considered high growth.
  • Arix Bioscience's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:3HY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Arix Bioscience Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3HY Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 0.08 0.08 0.08 1.00
2020-04-02
DB:3HY Past Financials Data
Date (Data in GBP Millions) EPS *
2019-12-31 -0.54
2019-09-30 -0.38
2019-06-30 -0.22
2019-03-31 0.04
2018-12-31 0.31
2018-09-30 0.28
2018-06-30 0.25
2018-03-31 0.10
2017-12-31 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Arix Bioscience will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Arix Bioscience's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Arix Bioscience has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Arix Bioscience performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Arix Bioscience's growth in the last year to its industry (Capital Markets).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Arix Bioscience does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Arix Bioscience's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Arix Bioscience's 1-year growth to the DE Capital Markets industry average as it is not currently profitable.
Earnings and Revenue History
Arix Bioscience's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Arix Bioscience Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3HY Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -58.14 -69.69 12.50
2019-09-30 -39.88 -48.70 13.65
2019-06-30 -21.63 -27.72 14.80
2019-03-31 15.43 4.58 14.91
2018-12-31 52.50 36.88 15.03
2018-09-30 47.44 30.88 14.67 0.10
2018-06-30 42.39 24.89 14.31 0.21
2018-03-31 24.89 8.71 14.37 0.21
2017-12-31 7.40 -7.47 14.44 0.21
2016-12-31 1.49 -6.63 11.25
2016-03-31 0.00 -7.19 6.20

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Arix Bioscience has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Arix Bioscience has efficiently used its assets last year compared to the DE Capital Markets industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Arix Bioscience improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Arix Bioscience's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Capital Markets industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Arix Bioscience has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Arix Bioscience's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Arix Bioscience's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Arix Bioscience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Arix Bioscience's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Arix Bioscience's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -5.0290796318919E+17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Arix Bioscience Company Filings, last reported 3 months ago.

DB:3HY Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 202.11 0.00 54.64
2019-09-30 202.11 0.00 54.64
2019-06-30 231.77 0.00 59.99
2019-03-31 231.77 0.00 59.99
2018-12-31 270.17 0.00 91.22
2018-09-30 270.17 0.00 91.22
2018-06-30 257.63 0.00 137.16
2018-03-31 257.63 0.00 137.16
2017-12-31 146.45 0.00 74.94
2016-12-31 46.33 0.00 28.93
2016-03-31 45.22 0.00 40.64
  • Arix Bioscience's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Arix Bioscience's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Information is not available.
  • Unable to confirm if Arix Bioscience has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Arix Bioscience's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Arix Bioscience has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Arix Bioscience's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Arix Bioscience dividends.
If you bought €2,000 of Arix Bioscience shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Arix Bioscience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Arix Bioscience's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:3HY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Germany Capital Markets Industry Average Dividend Yield Market Cap Weighted Average of 15 Stocks 3.3%
Germany Market Average Dividend Yield Market Cap Weighted Average of 320 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:3HY Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2020-04-02

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Arix Bioscience has not reported any payouts.
  • Unable to verify if Arix Bioscience's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Arix Bioscience's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Arix Bioscience has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Arix Bioscience's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Arix Bioscience afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Arix Bioscience has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Arix Bioscience's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joe Anderson
COMPENSATION £737,000
AGE 60
TENURE AS CEO 1.2 years
CEO Bio

Dr. Joseph Anderson, also known as Joe, Ph.D., has been the Chief Executive Officer and Co-Founder at Arix Bioscience plc., since February 2019. He serves as Director at Arix Bioscience plc since February 9, 2019. Dr. Anderson served as the Chief Investment Officer of Arix Bioscience plc since September 4, 2018 until February 2019. Dr. Anderson served as the Chief Executive Officer of Arix Bioscience plc since 2016 until September 4, 2018. He focuses on new investments and work with existing group companies to build and realise value. He leads IPO and recent fundraising at the firm. Dr. Anderson served as a Partner at Abingworth LLP, where he led venture-capital style investments in public companies. He joined Abingworth LLP in January 2004. Dr. Anderson led venture and growth equity investments in small public companies in the United States and Europe and managed open-market portfolios of small-cap public equities. He managed Abingworth's investments in public equities including post-IPO stage of former venture companies, open market transactions and private investments in public equities (PIPEs). Dr. Anderson was Head of Global Healthcare and Portfolio Manager at First State Investments (UK) Limited, where he launched and managed the Global Health and Biotechnology Fund and served as its Head of Healthcare Equities and Portfolio Manager. He was a part of the Commonwealth Bank of Australia, where Dr. Anderson was Head of Global Healthcare Equities and a Portfolio Manager. Dr. Anderson served as a Pharmaceuticals Analyst at Dresdner Kleinwort Benson. He served as Equity Analyst of Dresdner Kleinwort, Research Division. From 1990 to 1998, he began his career at Wellcome Trust and served as its Head of the Strategy Unit. Dr. Anderson led a team researching and advising the Board on investment opportunities in medical science globally at Wellcome Trust. He served as a Non-Executive Director of Autolus Therapeutics Plc. (Known as Autolus Limited) from February 2016 until June 15, 2018. He served as Additional Director at Cytos Biotechnology AG since May 2012. Dr. Anderson served as a Member of Supervisory Board at Epigenomics AG from June 08, 2010 to May 02, 2012. He served as a Director of Amarin Corporation plc from October 2009 to July 9, 2013. Dr. Anderson served as a Non-Executive Director of Algeta ASA from April 2009 to April 11, 2013. He has several years’ experience as an Analyst, Fund Manager and Investment Manager in the pharmaceutical and bioscience sectors. Dr. Anderson several years’ experience investing in private and public life sciences companies and extensive board level experience of building successful life sciences companies. He served as the Member of the Board of Directors at Arix Bioscience plc since February 8, 2016 until September 4, 2018. He holds a Ph.D. in Biochemistry and Bioscience from University of Aston and BSc First Class Hons in Biological Science Grade1st Class from Queen Mary College University of London.

CEO Compensation
  • Joe's compensation has increased whilst company is loss making.
  • Joe's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Arix Bioscience management team in years:

1.2
Average Tenure
57.5
Average Age
  • The average tenure for the Arix Bioscience management team is less than 2 years, this suggests a new team.
Management Team

Joe Anderson

TITLE
CEO, Co-Founder & Director
COMPENSATION
£737K
AGE
60
TENURE
1.2 yrs

Chris Evans

TITLE
Consultant
COMPENSATION
£134K
AGE
62
TENURE
1.2 yrs

Marcus Karia

TITLE
Group Finance Director
TENURE
0.5 yrs

Robert Lyne

TITLE
COO, General Counsel & Company Secretary

Charlotte Parry

TITLE
Head of Investor Relations

Matthew Cole

TITLE
Communications Director

Ed Rayner

TITLE
Investment Director

Jonathan Tobin

TITLE
Investment Director

Mark Chin

TITLE
Former Investment Manager
AGE
37

Christian Schetter

TITLE
Entrepreneur in Residence
AGE
55
Board of Directors Tenure

Average tenure and age of the Arix Bioscience board of directors in years:

1.4
Average Tenure
60
Average Age
  • The average tenure for the Arix Bioscience board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jon Peacock

TITLE
Non-Executive Chairman of the Board
COMPENSATION
£155K
AGE
61

Joe Anderson

TITLE
CEO, Co-Founder & Director
COMPENSATION
£737K
AGE
60
TENURE
1.2 yrs

Trevor Jones

TITLE
Independent Non-Executive Director
COMPENSATION
£50K
AGE
76
TENURE
4.2 yrs

Giles F. Kerr

TITLE
Independent Non-Executive Director
COMPENSATION
£60K
AGE
60
TENURE
2.5 yrs

Art Pappas

TITLE
Independent Non-Executive Director
COMPENSATION
£141K
AGE
71
TENURE
1.6 yrs

Mark Breuer

TITLE
Independent Non-Executive Director
COMPENSATION
£99K
AGE
56
TENURE
1 yrs

Naseem Amin

TITLE
Independent Non-Executive Director
COMPENSATION
£3K
AGE
57
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Arix Bioscience's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Arix Bioscience has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Arix Bioscience plc, formerly known as Perceptive Bioscience Investments Limited, is a venture capital firm specializing in seed, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is based in London, United Kingdom with an additional office in New York, New York.

Details
Name: Arix Bioscience plc
3HY
Exchange: DB
Founded: 2015
£86,529,448
130,471,268
Website: http://arixbioscience.com
Address: Arix Bioscience plc
20 Berkeley Square,
London,
Greater London, W1J 6EQ,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
LSE ARIX Ordinary Shares London Stock Exchange GB GBP 17. Feb 2017
DB 3HY Ordinary Shares Deutsche Boerse AG DE EUR 17. Feb 2017
BATS-CHIXE ARIXL Ordinary Shares BATS 'Chi-X Europe' GB GBP 17. Feb 2017
Number of employees
Current staff
Staff numbers
15
Arix Bioscience employees.
Industry
Asset Management and Custody Banks
Diversified Financials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/02 04:20
End of day share price update: 2020/04/01 00:00
Last estimates confirmation: 2020/03/19
Last earnings filing: 2020/03/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.